Szofia S. Bullain

Neurology
101 The City Dr S Bldg 53
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Erratum to "Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers" [The Journal of Prevention of Alzheimer's Disease volume 12 (2025) 100302].

Erratum to "Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers" [The Journal of Prevention of Alzheimer's Disease volume 12 (2025) 100302].

Journal: The journal of prevention of Alzheimer's disease
Published: November 18, 2025

Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.

Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.

Journal: The journal of prevention of Alzheimer's disease
Published: March 31, 2025

Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease.

Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease.

Journal: Nature aging
Published: March 14, 2025

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).

Journal: Journal of Alzheimer's disease : JAD
Published: December 17, 2024

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.

Journal: JAMA neurology
Published: November 18, 2024

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Journal: Journal of Alzheimer's disease : JAD
Published: August 23, 2024

Validation of 3- and 5-point severity scales to assess ARIA-E.

Validation of 3- and 5-point severity scales to assess ARIA-E.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: July 19, 2023

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: August 15, 2022

In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.

In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.

Journal: Alzheimer's & dementia (New York, N. Y.)
Published: February 22, 2022

What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.

What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.

Journal: Journal of neurochemistry
Published: December 06, 2019

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.

Journal: PloS one
Published: November 15, 2017

Late-Onset Alzheimer Disease.

Late-Onset Alzheimer Disease.

Journal: Neurologic clinics
Published: April 16, 2017
Showing 1-12 of 19

Last Updated: 09/26/2026